Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2023-03-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well auranofin and sirolimus work in treating participants
with ovarian cancer. Immunosuppressive therapy, such as auranofin and sirolimus, is used to
decrease the body?s immune response and may increase blood cell count.